Reapplix Seals In More Funding For Diabetic Foot Ulcer Patch
Executive Summary
Reapplix, an emerging autologous cell-based wound therapy specialist, has secured additional funding that will take the company through the next year before it gets “market-ready” to launch its diabetic foot ulcer treatment in the US and EU.